ProKidney announced mixed phase 2 trial outcomes for rilparencel, its autologous cell therapy targeting chronic kidney disease (CKD). One patient cohort receiving two injections demonstrated a statistically significant 78% slowing of kidney function decline, while another cohort showed a non-significant 50% improvement after a single injection with conditional dosing. Safety was favorable, and the company plans to seek FDA endorsement to use kidney function decline as a surrogate endpoint for an ongoing phase 3 trial. The results sustain optimism for rilparencel's potential in CKD management despite partial trial limitations.